Comparing MariMed (OTCMKTS:MRMD) and Stagezero Life Sciences (OTCMKTS:SZLSF)

MariMed (OTCMKTS:MRMD) and Stagezero Life Sciences (OTCMKTS:SZLSF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Insider and Institutional Ownership

0.2% of MariMed shares are owned by institutional investors. 19.0% of MariMed shares are owned by company insiders. Comparatively, 2.5% of Stagezero Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for MariMed and Stagezero Life Sciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MariMed	0	2	0	0	2.00
Stagezero Life Sciences	0	0	0	0	0.00

Earnings and Valuation

This table compares MariMed and Stagezero Life Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MariMed	$159.83 million	0.20	-$14.48 million	($0.03)	-2.63
Stagezero Life Sciences	N/A	N/A	N/A	($0.01)	-0.51

Stagezero Life Sciences has lower revenue, but higher earnings than MariMed. MariMed is trading at a lower price-to-earnings ratio than Stagezero Life Sciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

MariMed has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Stagezero Life Sciences has a beta of -4.43, suggesting that its share price is 543% less volatile than the S&P 500.

Profitability

This table compares MariMed and Stagezero Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MariMed	-8.94%	-5.85%	-1.58%
Stagezero Life Sciences	N/A	N/A	N/A

About MariMed

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

About Stagezero Life Sciences

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.